A detailed history of Voya Investment Management LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 23,350 shares of ALT stock, worth $168,353. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,350
Previous 124,139 81.19%
Holding current value
$168,353
Previous $825,000 82.67%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.5 - $8.1 $554,339 - $816,390
-100,789 Reduced 81.19%
23,350 $143,000
Q2 2024

Dec 03, 2024

BUY
$5.91 - $10.23 $595,662 - $1.03 Million
100,789 Added 431.64%
124,139 $825,000
Q2 2024

Aug 14, 2024

SELL
$5.91 - $10.23 $970,031 - $1.68 Million
-164,134 Reduced 56.94%
124,139 $825,000
Q1 2024

Dec 06, 2024

BUY
$8.22 - $13.81 $2.18 Million - $3.66 Million
264,923 Added 1134.57%
288,273 $2.93 Million
Q1 2024

May 15, 2024

BUY
$8.22 - $13.81 $2.2 Million - $3.7 Million
267,769 Added 1305.94%
288,273 $2.93 Million
Q4 2023

Feb 14, 2024

BUY
$2.14 - $11.62 $1,872 - $10,167
875 Added 4.46%
20,504 $230,000
Q2 2023

Aug 14, 2023

BUY
$3.45 - $5.97 $67,720 - $117,185
19,629 New
19,629 $69,000
Q2 2022

Aug 15, 2022

SELL
$3.94 - $11.77 $57,169 - $170,782
-14,510 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$8.69 - $12.48 $580,865 - $834,200
-66,843 Reduced 82.16%
14,510 $133,000
Q3 2021

Nov 15, 2021

BUY
$8.43 - $16.81 $577,960 - $1.15 Million
68,560 Added 535.92%
81,353 $920,000
Q2 2021

Aug 16, 2021

BUY
$9.85 - $16.46 $126,011 - $210,572
12,793 New
12,793 $126,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $353M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.